Pregabalin Market - By Formulation, By Application, By Distribution Channel & Global Forecast, 2025 - 2034

Pregabalin Market Size

The global pregabalin market size was valued at USD 1.8 billion in 2024. The market is expected to grow from USD 1.9 billion in 2025 to USD 3 billion in 2034, at a CAGR of 5.1%. The market for pregabalin is witnessing constant growth, with a rise in cases of neuropathic pain, epilepsy, and generalized anxiety disorder (GAD).
 

Being a commonly prescribed anticonvulsant and medication for neuropathic pain, pregabalin is popular due to its efficacy in treating long-lasting pain conditions and hence is a drug of choice among healthcare specialists as well as patients. The market is increasing with an upsurge in prescriptions through hospitals, retail pharmacies, and online portals, along with increased adoption in developing markets.
 

The market for pregabalin is significantly growing because of the increasing number of patients with neuropathic pain, epilepsy, and generalized anxiety disorder (GAD). For instance, the World Health Organization (WHO) states that around 50 million people around the world are living with epilepsy, which is one of the most prevalent neurological conditions worldwide.
 

Moreover, neuropathic pain resulting from nerve damage in diseases like diabetes, spinal cord injury, and chemotherapy is also on the rise across the world. For instance, the National Institutes of Health (NIH) reports that more than 50% of diabetic adults develop diabetic neuropathy, particularly in patients above 40 years of age. The established efficacy of pregabalin in the treatment of such conditions reinforces its position as a first-line therapy, thus contributing to market growth.
 

Additionally, the growing population of older adults has a major impact on the pregabalin market. For instance, according to the United Nations, by 2050, one in every six individuals globally will be aged above 65, compared to one in eleven in 2019. The rise in diabetic neuropathy, fibromyalgia, and post-herpetic neuralgia among older adults accelerates the demand for effective pain management drugs. Such a demographic change indicates the growing need for pregabalin in the treatment of age specific neurological problems.
 

Pregabalin Market Trends

• The innovations in drug delivery are transforming the diagnosis and treatment of pregabalin by introducing novel drug delivery systems that optimize therapeutic effects. The use of transdermal patches and nanotechnology based systems is increasing, as they enable enhanced treatment outcomes and ensure patient safety.
   
• The distribution of pregabalin has been impacted by the COVID-19 pandemic which has accelerated the use of online pharmacies. According to LogiNext, a software-based automation solution provider, e-commerce sales of medicine increased by 40% during the pandemic. During pandemic, patients were able to order medicines online at pharmacies which were delivered to their homes without any contact with the patient. The ongoing practice post-pandemic has driven up the sales across online platforms as compared to retail pharmacies. This shift in the sale and distribution of medicines is expected to grow during the forecast period.
   
• Additionally, healthcare professionals are embracing personalized medicine strategies in pregabalin prescriptions by taking into account genetic predispositions, concurrent health conditions, and patient’s response to previous treatments to maximize patient outcomes.
   
• Moreover, healthcare professionals are embracing personalized medicine approaches in the prescription of pregabalin by taking into consideration genetic predispositions, other medical conditions, and the patient’s response to previous treatments, to improve patient care.
   
• Furthermore, increased mental health consciousness has broadened the use of pregabalin in the treatment of mental disorders. For instance, according to Middle East Current Psychiatry, approximately 4.05% of the world's population suffers from an anxiety disorder, which amounts to 301 million individuals. Physicians increasingly use pregabalin to treat generalized anxiety disorder (GAD), backed by studies that prove its efficacy in the control of anxiety symptoms. The use of pregabalin in mental health treatment regimens continues to grow with increasing evidence of its therapeutic applications.
   

Pregabalin Market Analysis

Based on formulation, the market is bifurcated into tablets and capsules and oral solution. The tablets and capsules segment is expected to drive business growth and expand at a CAGR of 5.1%, reaching over USD 2.3 billion by 2034.
 

• The tablets and capsules are the preferred formulations due to the simplicity that comes with their use. In case of chronic pain, patients are finding tablets and capsule easier to consume when compared to liquid forms which may require more effort to manage.
   
• The introduction of dosage forms like tablets and capsules make dosages simple, this provides an accurate prescription based on the individual patient's needs. This increase in demand for easy dosage forms surges pregabalin industry growth and ensures increased medication adherence along with improved patient compliance.
   
•  Moreover, widespread use of pregabalin capsules and tablets in the management of neuropathic pain, especially for diabetic neuropathy, post herpetic neuralgia and fibromyalgia, supports the market growth.
   
• For instance, according to the National Fibromyalgia Association, about 3%-6% of people worldwide suffer from fibromyalgia. The increase in prevalence of these disorders together with the increasing elderly population who are vulnerable to chronic pain increases the need for easy to consume pain management solutions such as tablets and capsules, making these pregabalin formulations essential part of advanced pain management strategies.

Based on application, the pregabalin market is segmented into neuropathic pain, epilepsy, generalized anxiety disorder, and other applications. The neuropathic pain segment is expected to drive business growth and expand at a CAGR of 5.2%, reaching over USD 1.6 billion by 2034.
 

• The rising incidence of neuropathic pain disorders fuels market growth. Disorders like diabetic neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathy are on the rise due to reasons such as aging populations, the rising rate of diabetes, and the occurrence of specific cancers.
   
• For instance, according to the Journal of Pre-Clinical and Clinical Research, approximately 20% of patients aged older than 65 and up to 30% of those above 80, who develop herpes zoster (HZ), may develop postherpetic neuralgia (PHN). This increasing number of neuropathic pain conditions clearly points to growing patient numbers necessitating pregabalin treatment.
   
• In addition, growing understanding of neuropathic pain among patients and healthcare practitioners fuels the growth of market. There is an increase in the rates of diagnosis and treatment due to improved understanding of the symptom, cause, and management of neuropathic pain.
   

Based on distribution channel, the pregabalin market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The retail pharmacies segment generated a revenue of USD 1.2 billion in 2024.
 

• For the patients with pregabalin prescriptions, retail pharmacies are much more accessible than hospital pharmacies. The proximity of retail pharmacies reduces the travel time for the patients, especially those suffering from chronic conditions, which require constant medication. These accessible locations result in higher adherence to prescribed treatments, leading to an increased demand for pregabalin across retail pharmacy channels.
   
• Moreover, the expansion of retail pharmacy chains and the diversification of their services strengthens the distribution of pregabalin. Additionally, the retail pharmacies also offer additional services like medication therapy management and health screenings, thereby modifying their role in patient care delivery.

North America: The U.S. pregabalin market was valued at USD 754 million in 2024 and is projected to grow substantially in the coming years.
 

• The U.S. is confronting a growing incidence of neuropathic pain disorders, such as diabetic neuropathy and post-herpetic neuralgia. For instance, the Centers for Disease Control and Prevention (CDC) indicates that one in every 10 people in the U.S. have diabetes, with an estimated diagnosis in 28.7 million people in 2023.
   
• Moreover, the Journal of Pain Research estimates that about 10% of people in the United States suffer from neuropathic pain. Such a large patient population has made pregabalin a primary treatment option among physicians for the management of these disorders.
   
• Additionally, owing to the U.S. opioid crisis, patients and health specialists have shifted their focus to non-opioid painkillers. Pregabalin's reputation as a non-opioid drug has strengthened its position for the treatment of chronic pain conditions. The shift in focus towards non-opioid drugs has increased the need for pregabalin.
   

Europe: UK pregabalin market is projected to grow remarkably in the coming years.
 

• The UK market for pregabalin has expanded with the growing prevalence of diabetes and the aging population leading to an increase in diabetic neuropathy and post-herpetic neuralgia. For example, the Shingles Support Society states that out of the 194,000 people who get Shingles every year in Britain, more than 50 percent suffer from post herpetic neuralgia.
   
• In the UK, healthcare practitioners are increasingly using pregabalin as first line treatment for these painful conditions, thereby enhancing market growth. This increasing disease burden indicates a constant requirement for pregabalin in the UK.
   
• Additionally, organizations such as the National Institute for Health and Care Excellence (NICE) guidelines recommend pregabalin for the management of neuropathic pain and anxiety disorders. Such regulatory endorsement has boosted pregabalin uptake among healthcare professionals in the UK healthcare sector.
   

Japan holds a commendable position in the Asia Pacific pregabalin market.
 

• Japan's fast-aging population has escalated the number of age-related ailments, such as neuropathic pain and chronic diseases. For instance, according to the World Economic Forum (WEF), Japan boasts the largest percentage of elderly citizens in the world, with around 10% of its population aged 80 and older in 2023.
   
• Moreover, according to a report by the Health and Global Policy Institute (HGPI), 22.5% of Japanese adults, which translates to around 23.15 million individuals, experience chronic pain, fueling the need for pregabalin and other pain relief measures. This population shift greatly affects the market in Japan and facilitates a long-term demand for effective pain management drugs over the forecast period.
   
• Additionally, Japan's health system offers widespread access to medical care with an emphasis on patient-centered care. The extensive availability of healthcare facilities and pharmacies allows patients to receive timely diagnoses and treatments for chronic diseases that need pregabalin therapy.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the pregabalin market.
 

• The growth in diabetes and obesity, along with its complications in Saudi Arabia, has led to an increase in chronic conditions like neuropathic pain. For instance, according to the National Institutes of Health, the occurrence of diabetes in Saudi Arabia exceeds 25% of adults, making it one of the highest rates globally. This increasing burden of disease results in a growing demand for pain management medications, particularly pregabalin, which indicates a growing potential market for therapies targeting pain from diabetic neuropathy.
   
• Moreover, the Saudi Arabia government’s Vision 2030 program includes a significant allocation of funding for the improvement of medical services and infrastructure, as well as for expanding their accessibility. Hospital, clinic, and pharmacy developments are continuously augmenting patient accessibility to necessary medicines, such as pregabalin.
   

Pregabalin Market Share

The market for pregabalin is extremely fragmented with many pharmaceutical and biotechnology firms providing these treatments. The major players including Pfizer, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Aurobindo Pharma occupy around 40% of the market share with their experience in pregabalin innovation and huge production capacities. These major firms are investing extensively in sophisticated research and development processes to improve the stability, half-life, and efficacy of the drugs.
 

To address increasing demand, companies are forging strategic collaborations with contract manufacturers and research institutions to incorporate innovative technologies and increase effectiveness. In addition, simplified processes for the approval of pregabalin medications as well as regulatory assistance are fostering innovations and reducing market entry barriers. New entrants are focusing on new drug performance enhancing technologies, such as personalized medicine, combination therapies, and other novel drug formulations. This market dynamics stimulates continuous innovation processes in the supply of pregabalin with the aim of improving treatment options for various diseases.
 

Pregabalin Market Companies

Prominent players operating in the Pregabalin industry include:

• Alkem Laboratories
• Amneal Pharmaceuticals
• Apotex
• Aurobindo Pharma
• Cipla
• Dr. Reddy’s Laboratories
• Hikma Pharmaceuticals
• Lupin
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris
• Zydus Lifesciences
   
• Pfizer controls a considerable portion of the pregabalin formulations market owing to its strong brand portfolio. The competition along with the reputation of effective therapy in the region improves due to Pfizer’s geographical presence and its emphasis on new products’ development.
   
• Teva Pharmaceutical Industries is a specialist in the manufacturing of both branded and generic specialty medication. With Teva's experience in the pharmaceutical industry combined with the company’s focus on affordable healthcare, Teva is able to provide low-cost and high-quality pregabalin. The extensive supply chain and distribution infrastructure of Teva ensures their significant market presence.
   
• Due to a continued focus on affordable healthcare, Cipla has rapidly positioned itself as a leading competitor in the market. Cipla formulates high-quality generic drugs which aid in making pregabalin accessible to patients. Cipla also endorses an innovative drug formulation with strong emphasis on research and development, making it a reputable provider of effective treatment across numerous therapeutic classes.
   

Pregabalin Industry News:

• In April 2023, Aurobindo Pharma Limited announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Pregabalin Capsules in various strengths, including 25 mg to 300 mg, indicated for managing neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury, as well as for adjunctive therapy in adult patients with partial onset seizures. This approval enhanced Aurobindo Pharma's market presence and provides an opportunity to meet the growing demand for effective pain management solutions.
   
• In May 2022, Lupin Limited announced that it received approval from the U.S. FDA for its Pregabalin Capsules in strengths of 25 mg to 300 mg. These capsules were indicated for the treatment of pain caused by nerve damage due to diabetes or shingles. This approval strengthened Lupin's position in the market and enabled the company to expand its reach.
   
• In December 2022, Zydus Lifesciences Limited received approval from the U.S. FDA to market Pregabalin Capsules in strengths ranging from 25 mg to 300 mg. This approval positioned Zydus Lifesciences to expand its product portfolio and meet the growing demand for effective treatments for neuropathic pain.
   

The pregabalin market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Formulation

• Tablets and capsules
• Oral solution

Market, By Application

• Neuropathic pain
• Epilepsy
• Generalized anxiety disorder
• Other applications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE